

## 7. Conclusions

In the US and throughout the world, many non-scientific factors contribute to defining AM scope and the context for its evaluation. Therefore, to reach optimal integration, it is critical to take into account those many factors. For example, it is important to improve academic freedom for investigators to explore the variety of traditional medical systems, even if the principles they study seem to be difficult to reconcile with conventional biomedicine, at present. There is a welcome change in this direction since the NIH funded several academic centers dedicated to AM assessment at major US institutions.<sup>40</sup> We feel that, as another important factor in the development of AM, the alternative community should refrain from uncritical and premature enthusiasm for experimental results and theoretical implications that have not yet been thoroughly evaluated. While building theoretical models is intrinsic to the development of science, it is important to accumulate sufficient information and knowledge on the observed phenomena, based on solidly confirmed observations, instead of prematurely proposing hypothetical mechanisms.

The effort to take advantage of both alternative or traditional healthcare and mainstream Western medicine should be seen as a great opportunity, provided that the conceptual framework of systems is also taken into account along with the techniques and products used by these systems. Internationally, we have the opportunity to research, understand and mobilize a wider range of therapies to individualize clinical approaches, a trend seen by some as intrinsically and medically worthwhile. Such diversity of potential therapies and practices could result in more effective healthcare approaches, tailored to local or personal constraints as well as preferences, and to improved functioning of the medical, economic, political and social infrastructures as they impact on healthcare.

In this time of great scientific and medical opportunity and change, considerable economic promise exists in the growing markets derived from the increased use of alternative as well as high-tech medicine.

We hope that beyond a focus on developing profitable AM products, there will also be an abiding interest in improving world healthcare. Improvement in healthcare should include an attempt to understand and address the underlying issues that have prompted the public to seek AM practices, based on a clearer conceptualization of the nature and role of those therapies currently deemed alternative. All non-scientific and scientific factors that are shaping this unusually heterogeneous and potentially fruitful field must be taken into account for a thoughtful evaluation to yield more than incremental progress. More rapid and thoroughgoing progress in integrating medicine could yield multiple benefits of greatly improved healthcare worldwide, which in turn would support national as well as global economic and social progress, at the same time exploring important and exciting new areas of research.

## References

1. Eisenberg D.M., Kessler R.C., Foster C., *et al.* Unconventional medicine in the United States: prevalence, costs and patterns of use. *N. Engl. J. Med.* **328**, 245–252 (1993).
2. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M. and Kessler R.C. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. *JAMA* **280**(18), 1569–1575 (November 1998).
3. Astin J.A. Why patients use alternative medicine: results of a national study. *JAMA* **279**(19), 1548–1553 (1998).
4. *The Landmark Report on Public Perceptions of Alternative Care. 1998 Nationwide Study of Alternative Care* (Landmark Healthcare, Inc., California; and InterActive Solutions, Grand Rapids, Michigan, 1998).
5. *Alternative Medicine: Expanding Medical Horizons: A Report to the NIH on Alternative Medical Systems and Practices in The United States* (Washington, D.C., National Institutes of Health, 1995).
6. MacLennan A.H., Wilson D.H. and Taylor A.W. Prevalence and cost of alternative medicine in Australia. *Lancet* **347**, 569–573 (1996).
7. Integrated Health Care – A way forward for the next five years, in 1997; *Foundation for Integrated Medicine* (on behalf of the steering

- committee for the Prince of Wales's Initiative on Integrated Medicine – ISBN 1-85717-173-X).
8. Fisher P. and Ward A. Complementary medicine in Europe. *Br. Med. J.* **309**, 107–111 (1994).
  9. Chez R.A. and Jonas W.B. The challenge of complementary and alternative medicine. *Am. J. Obstet. Gynecol.* **177**, 1156–1161 (1997).
  10. Ernst E. (ed.) *Complementary Medicine – An Objective Appraisal* (Butterworth Heinemann, Oxford, 1996).
  11. Publication No. 102-170, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, HR 102-282 (1992): 29. [Conference Report].
  12. NIH Revitalization Act of 1993, HR 4 (1993): 117.
  13. Micozzi M.S. (ed.) *Fundamentals of Complementary and Alternative Medicine* (Churchill Livingstone, New York, 1996).
  14. Wetzel M.S., Eisenberg D. and Kaptchuk T. Courses involving complementary medicine and alternative medicine at US medical schools. *JAMA* **280**, 784–787 (1998).
  15. Bhattacharya B. M.D. programs in the United States with complementary and alternative medicine education: an ongoing listing. *J. Alt. Complement. Med.* **4**(3), 325–335 (1998).
  16. Benfield H. and Korngold E. *Between Heaven and Earth – A Guide to Chinese Medicine* (Ballantine Books, New York, 1991), Vol. 5.
  17. Wise T.A. Origin and history of medicine, in *The Hindu System of Medicine* (Mittal Publishers, New Delhi, 1986), pp. 1–11.
  18. Donden Y. *Health Through Balance: An Introduction to Tibetan Medicine* (ed.) Hopkins J. (Snow Lion, New York, 1986).
  19. Eskinazi D. Factors that shape alternative medicine. *JAMA* **280**(18), 1621–1623 (1998).
  20. *Merriam-Webster Collegiate Dictionary*, 10th Ed. (Merriam-Webster, Inc., Massachusetts, 1993).
  21. *Transcripts of the Alternative Medicine Program Advisory Committee Meetings, September 1994–1997* (Washington, D.C., Alternative Medicine Program Advisory Committee, 1994–1997).
  22. *Hearing Before the Subcommittee on Appropriations, United States Senate, 103rd Congress, 2nd Session, 1993* (special hearing).
  23. Jonas W. *Director Designee's Address*. Presented at meeting of the Alternative Medicine Program Advisory Committee, 21 March, 1995, Washington, D.C.

24. Siegfried J.D. The drug development and approval process. *Pharma Newsl.* (January 1998).
25. Burkholtz H. *The FDA Follies* (Basic Books, New York, 1994), p. 12, 110, 114.
26. Eskinazi D. (ed.) NIH technology assessment workshop on alternative medicine: acupuncture *J. Alt. Complement. Med.* **2**, 1–256, special issue (1996).
27. Eskinazi D.P. and Hoffman F.A.H. Progress in complementary and alternative medicine: contribution of the National Institutes of Health and the Food and Drug Administration. *J. Alt. Complement. Med.* **4**(4), 459–467.
28. Eskinazi D., et al. (eds.) *Botanicals: A Role in US Health Care*. Mary Ann Liebert, Inc., New York, 1999.
29. Cambridge Health Resources, et al. *Conference. Integrative Medicine: Business and Clinical Management*, 3–4 June 1999, San Francisco, California.
30. Stanford University, Center for Research in Disease Prevention, School of Medicine; and Beth Israel Deaconess Medical Center (affiliated, Harvard Medical School), Boston, Massachusetts, Center for Alternative Medicine Research and Education. *First Annual Conference. Complementary and Alternative Medicine: Practical Applications and Evaluations*, 15–17 October 1999, San Francisco, California.
31. Lazarou J. and Pomeranz B.H. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* **279**(15), 1220–1205 (1998).
32. Stolberg S.G. The boom in medications brings rise in fatal risks. Death by prescription. Part I of II. *The New York Times*, 3 June 1999, pp. A1, A24.
33. Stolberg S.G. Faulty warning labels add to risk in prescription drugs. Death by prescription. Part II of II. *The New York Times*, 4 June 1999, p. A27.
34. Parfitt A. Acupuncture as an antiemetic treatment. In NIH technology assessment workshop on alternative medicine: acupuncture (ed.) Eskinazi D. *J. Alt. Complement. Med.* **2**, 1–256 (1996). Special issue, pp. 167–174.
35. Schiff M. *The Memory of Water* (Harper Collins, London, 1995).
36. Benveniste J. Dr. Jacques Benveniste replies. *Nature* **334**, 291 (1988).
37. Fugh-Berman A. *Alternative Medicine: What Works*. (Odonian Press, Arizona, 1996), pp. 50–52.

22 The Future of Alternative Medicine

38. Stacey M. The fall and rise of Kilmer McCully. *The New York Times, Magazine Section*, 10 August 1997.
39. Blank M. and Goodman R. Letter to the editor: The fall and rise of Kilmer McCully. *The New York Times, Magazine Section*, 7 September 1997.
40. Office of Alternative Medicine Home Page, Core CAM Presentations, Slide #42: Centers (<http://altmed.od.nih.gov/oam/resources/present/cam-core/>)